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The transcription factor PU.1, encoded by the Sfpi1
gene, functions in a graded manner to regulate
macrophage versus B cell generation; its higher
concentration favors the macrophage fate. We
demonstrated that Gfi1 reciprocally promoted B cell
fate choice at the expense of myeloid progeny.
Gfi1-/-multipotential progenitors (MPPs) were unable
to constrain the expression of PU.1 because Gfi1
functioned to repress the Sfpi1 gene by displacing
PU.1 from positive autoregulatory elements. Attenu-
ating a transcriptional module composed of PU.1
and Egr suppressed the B lineage developmental
defects ofGfi1-/-MPPs. Finally Ikaros, a transcription
factor required forBcell development, promotedGfi1
and antagonized PU.1 expression in MPPs. Our
results reveal that a core transcriptional regulatory
network used for directing cell fate choice in the
innate immune system has been co-opted by Ikaros
to orchestrate B lymphocyte generation. These find-
ings have important implications for the evolution of
the adaptive immune system.
INTRODUCTION
An emerging developmental framework for hematopoiesis posits
that cells of the innate and adaptive immune system arise from
a common lymphoid-primed multipotent progenitor (LMPP)
lacking erythrocytic and megakaryocytic potential (Adolfsson
et al., 2005; Laiosa et al., 2006a). Genetic and molecular anal-
yses of various lineage-determining transcription factors have
enabled the assembly of contingent gene regulatory networks
that promote the generation of either myeloid or lymphoid
progeny from multipotent hematopoietic progenitors (Laiosa
et al., 2006a; Laslo et al., 2008; Rothenberg and Taghon, 2005;
Singh et al., 2005). Although the transcription factors PU.1,
Ikaros, Mef2c, E2A, and EBF1 have been implicated in regulating
myeloid versus lymphoid cell fate choice (DeKoter and Singh,
2000; Dias et al., 2008; Pongubala et al., 2008; Reynaud et al.,
2008; Stehling-Sun et al., 2009), the nature of the molecular576 Immunity 31, 576–586, October 16, 2009 ª2009 Elsevier Inc.circuits that underlie the onset of cell fate determination in
MPPs remain to be elucidated. A deeper understanding of such
transcriptional networks may provide insight into the molecular
evolution of the adaptive immune cells from their primordial
innate counterparts.
The existence of multipotent progenitors restricted to the
generation of myeloid and lymphoid progeny was previously
proposed on the basis of genetic analysis of the gene encoding
PU.1 (Sfpi1) (Singh, 1996; Singh et al., 1999). PU.1 is a member
of the Ets family of transcription factors and is expressed in
multiple lineages of the hematopoietic system, including MPPs
(Nutt et al., 2005). In the absence of PU.1, the development of
myeloid and lymphoid lineages is severely impaired, whereas
the generation of erythrocytes and megakaryocytes is largely
unaffected (McKercheret al., 1996;Scott etal., 1994). Theexpres-
sionofmanymyeloid (DeKoter et al., 1998) and lymphoid-specific
genes (DeKoter et al., 2002; Medina et al., 2004) is abolished in
PU.1-deficient (Sfpi1/) hematopoietic progenitors. Graded
amounts of PU.1 appear to regulate the development of myeloid
and B lineage progeny, given that a low concentration of PU.1
induces the B cell fate, whereas a higher concentration promotes
macrophage development at the expense of B cell generation
(DeKoter and Singh, 2000). In addition, elevating expression of
PU.1 has been shown to inhibit early T cell development (Ander-
son et al., 2002) and promote macrophage differentiation (Laiosa
et al., 2006b). These results suggest that PU.1 expression needs
to be constrained in MPPs in order to enable B lymphopoiesis in
the bone marrow and T lymphopoiesis in the thymus. The molec-
ular means by which this is achieved remains to be elucidated.
In myeloid progenitors, PU.1 has been shown to induce and
resolve a mixed lineage pattern of gene expression resulting in
the generation of macrophages and neutrophils (Laslo et al.,
2006). In this cellular context, PU.1 is a component of a transcrip-
tional regulatory circuit composed of the myeloid determinant
C/EBPa and the counteracting repressors Egr1,2, Nab2, and
Gfi1. High expression of PU.1 induces Egr2 and Nab2. Impor-
tantly, Egr2 functions in a feed-forward loopwith PU.1 to activate
macrophage-specific genes and with Nab2 to repress alternate
lineage neutrophil genes, including Gfi1. Conversely, Gfi1
promotes neutrophil differentiation by antagonizing PU.1 and
Egr activity, the former, presumably, via direct protein-protein
interactions (Dahl et al., 2007) and the latter via transcriptional
repression (Laslo et al., 2006). Because PU.1 expression
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et al., 2005), these results raised the possibility that Gfi1 could
attenuate expression of PU.1 by antagonizing PU.1 activity in
MPPs, thereby lowering its expression to promote the genera-
tion of lymphocytes at the expense of myeloid progeny.
Like PU.1, Gfi1 is expressed in multiple hematopoietic line-
ages, including MPPs (Hock et al., 2004; Zeng et al., 2004).
However, Gfi1 expression appears to be inversely correlated
with that of PU.1 in hematopoietic cells.Gfi1/ animals are neu-
tropenic; the granulocytic intermediates that develop in the bone
marrow misexpress PU.1-regulated genes such as Csf1r (Hock
et al., 2003). Interestingly, the frequency of myeloid progeny is
increased in the bone marrow of Gfi1/ mice, whereas the
number of B lineage cells in the bone marrow and T lineage cells
in the thymus are significantly reduced (Hock et al., 2003; Yucel
et al., 2003). Because high amounts of PU.1 function to induce
myeloid development and Gfi1 activity is critical in early lympho-
cyte development, we considered whether PU.1 and Gfi1 might
function in an antagonistic manner to regulate innate versus
adaptive immune cell fate choice in MPPs as they do in orches-
trating macrophage versus neutrophil development. Given that
high amounts of PU.1 are inhibitory for early B and T cell devel-
opment, we reasoned that the underlying basis might involve
PU.1-mediated induction of the Egrs that could directly repress
Gfi1 expression. Consistent with this possibility, the loss of
Egr1 results in increased T lineage precursors in the thymus
(Bettini et al., 2002). Given the aforementioned findings, we
hypothesized that a network composed of PU.1, Egrs, and
Gfi1 might function in a recurrent manner to regulate myeloid
versus lymphoid cell fate choice in MPPs.
As with Gfi1, the loss of the zinc-finger transcription factor
Ikaros has profound consequences on the development of
both B and T lineage cells (Wang et al., 1996). Additionally, Ikaros
has been implicated in the generation of LMPPs (Yoshida et al.,
2006). Interestingly, Ikaros-deficient (Ikzf1/) pro-B cells retain
myeloid developmental potential and misexpress multiple
myeloid-specific genes, including Csf1r (Reynaud et al., 2008).
These findings suggest similar roles for Ikaros and Gfi1 in
promoting early B and T cell development and in repressing
myeloid developmental potential. We therefore considered the
possibility that Ikaros and Gfi1 may represent components of
a regulatory network in which they collaborate to promote
adaptive immune cell fates and repress innate immune cell fates
in MPPs.
We designed a set of genetic and molecular experiments to
test the existence of the proposed regulatory network controlling
innate versus adaptive immune cell fates. We demonstrate that
Gfi1 promoted B cell fate choice by antagonizing the expression
of the gene encoding PU.1 and aspects of the myeloid gene-
expression program in MPPs. Molecular analyses revealed that
Gfi1 directly repressed the Sfpi1 gene by targeting the Sfpi1
promoter and a distal upstream regulatory element (URE).
Consistent with our hypothesis, Egr transcription factors were
shown to function in an opposing manner to Gfi1, given that
they inhibited B cell development while enabling myelopoiesis.
Finally, we showed that Ikaros positively regulated Gfi1 and
antagonized the expression of PU.1 in MPPs. These data are
consistent with a model whereby Ikaros and Gfi1 function within
MPPs to inhibit myeloid lineage potential by attenuating PU.1and Egr activity, thereby facilitating the specification of lymphoid
cell fates.
RESULTS
Gfi1 Promotes B Cell Fate Choice
Because Gfi1/ animals exhibit a decrease in the frequency of
common lymphoid progenitors and an increase in granulocyte
and macrophage progenitors (Zeng et al., 2004), we examined
whether Gfi1 functions to promote B cell fate specification and
repress myeloid development in the context of a MPP. We
isolated MPPs fromwild-type (WT) andGfi1/mice (Figure S1A
available online) and plated equivalent numbers on OP9 stroma
under conditions that support the generation of both myeloid
(Mac1+) and B lineage (CD19+) progeny. WT progenitors gave
rise to both myeloid (21%) and B lymphoid cells (68%). In
contrast, MPPs lacking Gfi1 were severely defective for B cell
development in vitro (Figure 1A and Figure S1B). We note that
the loss of Gfi1 in vivo impairs, but does not eliminate, B cell
development (Hock et al., 2003). We also performed gain-
of-function analyses to test whether an increased concentration
of Gfi1 in MPPs enhanced the generation of B lineage progeny at
the expense of myeloid precursors. Transduction of WT MPPs
with a control vector (MIGR1) via coculture primarily generated
Mac1+ cells. In contrast, MPPs transduced with a Gfi1 vector
(MIGR1-Gfi1) generated a higher proportion of CD19+ progeny
(Figure 1B). With limiting-dilution assays, MPPs transduced
with Gfi1 were seen to give rise to B lineage progeny at
Figure 1. Gfi1 Regulates B versus Myeloid Cell Fate Choice
(A) MPPs (LinSca-1+c-Kithi) were isolated from the bone marrow of WT or
Gfi1/ animals. Cells were directly plated on OP9 stroma and analyzed by
flow cytometry at day 12. Data are representative of at least three independent
experiments.
(B)WTMPPswere transducedwith a control vector (MIGR1) or one expressing
Gfi1 (MIGR1-Gfi1). GFP+ transductants were plated on OP9 stroma and exam-
ined for the generation of myeloid and B lineage progeny after 7 days. Data are
representative of at least three independent experiments.Immunity 31, 576–586, October 16, 2009 ª2009 Elsevier Inc. 577
Immunity
Regulation of B versus Myeloid Cell Fatesa frequency nearly 3.5 times higher than their control counter-
parts (Figure S1C). These results demonstrate that Gfi1
promotes B cell fate choice at the expense of myeloid options
in the context of MPPs.
Gfi1 Antagonizes PU.1 Expression in MPPs
PU.1 expression is elevated in total bone marrow cells lacking
Gfi1 (Hock et al., 2003). We specifically analyzed the expression
of PU.1 and other hematopoietic determinants inWT andGfi1/
MPPs. Whereas the expression of Ikaros and Gata1 were unaf-
fected in Gfi1/MPPs, PU.1 transcripts were elevated (Figures
2A and 2B). Moreover, the expression of theCsf1r gene, which is
directly activated by PU.1 (Krysinska et al., 2007), was increased
in Gfi1/ MPPs (Figures 2A and 2B). We note that Flt3 tran-
scripts are reduced in Gfi1/ MPPs (Figure 2B), consistent
with reduced Flt3 expression on the surface of Gfi1/ MPPs
(Hock et al., 2004; Zeng et al., 2004). We also assessed expres-
sion of c-fms and FcgRII and III on Gfi1/ MPPs by using flow
cytometry. Like c-fms, the FcgRII and FcgRIII receptors are
expressed on myeloid precursors and their genes are directly
activated by PU.1. The loss of Gfi1 resulted in increased expres-
sion of c-fms, FcgRII, and FcgRIII in MPPs (Figure 2C). We note
that the expression of Ly6G and Mac1, two cell-surface markers
that are expressed on more mature myeloid cells, was not
affected (Figure S2A). Thus, loss of Gfi1 results in elevated
expression of PU.1 and its myeloid target genes in MPPs.
We evaluated the developmental potential of c-fms express-
ing MPPs to test whether they were biased toward myeloid
Figure 2. Gfi1/ MPPs Express Increased
Amounts of PU.1 and Its Target Genes
(A) Semiquantitative RT-PCR analysis of cDNA
(33 serial dilution) fromWT orGfi1/MPPs. Tran-
script amounts were normalized to Hprt.
(B) qPCR analysis of PU.1, c-fms, and Flt3
transcripts in WT or Gfi1/ MPPs.
(C) Histograms represent c-fms or FcgRII&III
expression on the surface of WT (gray shaded
area) or Gfi1/ (black line) MPPs.
(D and E)WT orGfi1/MPPswere plated inmeth-
ylcellulose containing erythropoietin, stem cell
factor, IL-3, IL-6, and Flt3 ligand. Colony numbers
were scored 8 days after plating and analyzed for
the generation of CFU-Mix (erythroid-granulocyte-
macrophage), CFU-M (macrophage), or CFU-GM
(granulocyte-macrophage) by Wright staining of
cytospins. Data are from two independent experi-
ments. Error bars represent the standard deviation
from the mean.
fates (Figure S2B). Gfi1/ MPPs that
were c-fms had considerably lower
B lineage developmental potential than
WT MPPs (Figure S2B). Importantly,
c-fms+ MPPs lacking Gfi1 were further
impaired in their ability to give rise to
B lineage progeny. Therefore, B lineage
potential may be impaired in Gfi1/
MPPs as a consequence of enhanced
myeloid potential.
We predicted that augmented PU.1 expression in Gfi1/
MPPs should result in enhanced macrophage potential. We
analyzed Gfi1/ MPPs for their ability to undergo multilineage
erythro-myeloid differentiation. The absence of Gfi1 resulted in
50% reduction in plating efficiency of MPPs relative to WT
counterparts (Figure 2D). WT MPPs preferentially gave rise to
granulocyte-macrophage colonies (70%) and, to a lesser
extent, macrophage (25%) and myelo-erythroid colonies (5%)
(Figure 2E). In contrast, the preponderance of colonies gener-
ated from Gfi1/ MPPs contained macrophages (85%). No
discernable difference was noted between WT and Gfi1/
MPPs in the generation of myelo-erythroid colonies, suggesting
a role for Gfi1 in lineage restriction subsequent to the specifica-
tion of megakaryocyte and erythrocyte fates. Taken together,
these data suggest a critical role for Gfi1 in constraining the
expression of PU.1 in the context of two distinct cell fate choices:
(1) macrophage versus neutrophil and (2) myeloid versus B cell.
PU.1 Heterozygosity Partially Rescues B Cell
Development in Gfi1/ Mice
Given that the loss of Gfi1 results in enhanced expression of
PU.1, we reasoned that this may partially account for the
reduced B cell developmental potential of Gfi1/ MPPs. To
test this possibility, we determined whether reducing the dosage
of PU.1 would suppress the B cell developmental defect caused
by the loss of Gfi1. As previously described (Hock et al., 2003),
loss of Gfi1 resulted in fewer committed B lineage cells
(B220+CD19+) in the bone marrow (Figure 3A). Combining PU.1
578 Immunity 31, 576–586, October 16, 2009 ª2009 Elsevier Inc.
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the frequency as well as the absolute numbers of committed
B lineage cells (Figures 3A and 3B). In addition, there was a
2-fold increase in the number of pro-B cells (B220+CD43+) in
Gfi1/Sfpi1+/ mice in comparison to Gfi1/ controls (Fig-
ure 3B). These results demonstrate that B lineage defects in
Gfi1/ bone marrow can be partially suppressed by reducing
Sfpi1 gene dosage.
To determine whether reduced Sfpi1 gene dosage increases
the B lineage developmental potential of Gfi1/ MPPs, we
quantitatively analyzed their cell fate outputs in vitro. We note
that loss of one allele of Sfpi1 was associated with a decrease
in c-fms, FcgRII, and FcgRIII expression on the cell surface of
Gfi1/Sfpi1+/MPPs relative to their Gfi1/ counterparts (Fig-
ure S3). WT MPPs gave rise to B lineage cells at a frequency of
1/24, whereas loss of Gfi1 severely impaired the generation
of such cells (1/1260) (Figure 3C). Importantly, we observed
3.5-fold increase (1/360) in the frequency of B lineage cells
generated from Gfi1/Sfpi1+/ MPPs compared with their
Gfi1/ counterparts. These data demonstrate that Gfi1-medi-
ated antagonism of PU.1 expression in MPPs plays an important
role in restraining myeloid differentiation and, in turn, promoting
specification of the B cell fate.
Attenuation of PU.1 in Gfi1/ MPPs Promotes B Cell
Development
We utilized a shRNA approach to rigorously test whetherGfi1/
MPPs are impaired in their B lineage potential because of
Figure 3. PU.1 Heterozygosity Promotes B
Cell Development in Gfi1/ Mice
(A) Bone marrow cells from WT, Gfi1/, and
Gfi1/Sfpi1+/ animals were analyzed by flow cy-
tometry for B lineage (B220+CD19+) and myeloid
(Mac1+) precursors.
(B) Absolute numbers of B lineage (B220+CD19+
or B220+CD43+) cells in the bone marrow of WT
(n = 5), Gfi1/ (n = 5), and Gfi1/Sfpi1+/ (n = 7)
animals.
(C) Quantitative analysis of B lineage potential in
MPPs from WT (solid line), Gfi1/ (long dashed
line), or Gfi1/Sfpi1+/ (short dashed line) mice.
MPPs were plated on OP9 stroma in limiting dilu-
tion as described in Figure 1. Cultures were
analyzed for wells containing CD19+ cells at day
12. Data are representative of two independent
experiments. Error bars represent the standard
deviation from the mean.
increased expression of PU.1. Transduc-
tion of WT MPPs with a vector targeting
PU.1 mRNA (MSCV-shPU.1) resulted in
70% reduction in PU.1 transcripts and
its target geneCsf1r (Figure 4A). Reduced
PU.1 expression impaired terminal
myeloid differentiation, as evidenced by
the accumulation of c-Kit+Mac1+ myeloid
precursors (Figure 4B). This resembled
the accumulation of similar myeloid
precursors in the bone marrow of mice
in which PU.1 expression is reduced by targeting an upstream
distal enhancer (Rosenbauer et al., 2004). Importantly, attenua-
tion of PU.1 expression in WT MPPs resulted in a higher
frequency of committed B lineage progeny (27%) and dimin-
ished Mac1+ precursors (52%) compared to control transduc-
tants (Figure S4). Thus, lowering PU.1 expression in MPPs
promoted the generation of B lineage cells at the expense of
myeloid precursors.
We next examined whether attenuating PU.1 expression in
Gfi1/ MPPs restored their ability to give rise to B lineage
progeny. Gfi1/ MPPs were transduced with the control or
MSCV-shPU.1 construct. Although Gfi1/ MPPs primarily gave
rise to Mac1+ precursors, attenuation of PU.1 strongly induced
the generation of CD19+ B lineage cells (Figure 4C). These data
establish that Gfi1-mediated antagonism of PU.1 expression in
MPPs is used to regulate B versus myeloid cell fate choice.
Inhibition of Egr Activity Promotes B Cell Fate Choice
Wehave previously proposed that higher amounts of PU.1 antag-
onize Gfi1 expression via induction of the Egr’s which directly
bind to the Gfi1 promoter and repress its activity (Laslo et al.,
2006). Conversely, Gfi1 represses the transcription of Egr genes.
Thus, perturbing Egr activity would be predicted to have the
opposite consequence to that of manipulating Gfi1 on early B
cell development. Furthermore, the Egrs should promote myeloid
versus B cell fate choice in MPPs as is seen with a higher concen-
tration of PU.1. To test this prediction, we transduced WT
MPPs with a control vector (MIGR1) or one expressing
Immunity 31, 576–586, October 16, 2009 ª2009 Elsevier Inc. 579
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control transductants preferentially give rise to Mac1+ precursors,
inhibition of Egr function in MPPs strongly promoted the develop-
ment of B lineage progeny (Figure 5A). Limiting-dilution analyses
revealed that blocking Egr activity in MPPs enhanced B cell devel-
opment by more than an order of magnitude (Figure 5B). Thus,
blocking Egr activity in MPPs has similar consequences on B
cell development as enhancing Gfi1 expression (Figure 1B).
We next used genetic interaction analyses to test for the
functional cross-antagonism between the Egrs and Gfi1 in B
cell development. Interestingly, we observed that the removal
of Egr1 partially suppressed the B cell developmental defect
observed in Gfi1/mice (Figure 5C and Figure S5A). This paral-
leled the partial ‘‘rescue’’ of B cell development inGfi1/mice by
reducing the dosage of PU.1 (Figures 3A and 3B). Egr1 and Egr2
function redundantly during macrophage differentiation (Laslo
et al., 2006). To test whether Egr1 and Egr2 also function redun-
dantly in antagonizing the generation of B cells, we generated
mice lacking both Egr1 andEgr2 by using a conditionalEgr2 allele
(Taillebourg et al., 2002). This was necessary because Egr2/
mice die soon after birth (Swiatek and Gridley, 1993) and loss
of Egr1 and Egr2 results in embryonic lethality. Using the Mx1-
Cre transgene, we observed efficient excision of the Egr2 allele
in total bone marrow cells 4 weeks after polyIC treatment
(Figure S5B). Combined loss of Egr1 and Egr2 resulted in a 2-
fold increase in the percentage of B lineage progeny in the
bone marrow and a comparable reduction in myeloid precursors
(Figures S5B and S5C). These results provide compelling genetic
evidence in support of the hypothesis that Egrs antagonize B cell
fate choice at the expense of myeloid options in MPPs.
Gfi1 Targets the Sfpi1 Promoter and URE
Given that Gfi1 functions as a transcriptional repressor, we
examined whether Gfi1 targets the Sfpi1 gene, which encodes
PU.1. Bioinformatic analysis revealed conserved putative Gfi1
binding sites in the PU.1 promoter and the URE (Figure S6A).
Intriguingly, these presumptive Gfi1 binding sites were in close
proximity to PU.1 binding sites. PU.1 binding sites in the
promoter and URE of the Sfpi1 gene have been implicated in
a positive autoregulatory feedback loop (Okuno et al., 2005).
We considered the possibility that Gfi1 could repress the Sfpi1
gene by displacing PU.1 from its own promoter and URE.
We performed electrophoretic mobility-shift assays (EMSAs)
to determine whether PU.1 and Gfi1 recognize the predicted
binding-site motifs in the promoter and URE. PU.1 and Gfi1
bound to their respective motifs in the URE with higher affinity
than to the corresponding motifs in the promoter (Figure S6B).
Given that the Gfi1 and PU.1 sites overlap within the URE, we
tested whether the proteins compete for DNA binding. Competi-
tion reactions revealed PU.1 and Gfi1 displace each other when
binding to the composite element in the URE (Figure 6A).
To determinewhether Gfi1 andPU.1 bind to theURE in a recip-
rocal manner in vivo, we performed chromatin immunoprecipita-
tion (ChIP) assays with a cell line that expresses an inducible
PU.1 protein (PUER) (Walsh et al., 2002). In the absence of
tamoxifen (OHT), these cells express Gfi1 (Laslo et al., 2006),
which could be seen to crosslink to the URE (Figure 6B) as well
as the PU.1 promoter (Figure S6C, left panel). A basal amount
of crosslinking of PU.1 was also detectable at these regions
(Figure 6B and Figure S6C, left panel). Upon stimulation with
OHT, PU.1 binding at the URE and promoter increased, whereas
Gfi1 crosslinking was diminished (Figure 6B and Figure S6C, left
panel). Increased PU.1 binding accompanied by the loss of Gfi1
was also observed at the Csf1r promoter (Figure S6C, right
panel), consistent with recent findings implicating Gfi1 in the
repression of the Csf1r gene (Zarebski et al., 2008). Although
induction of PU.1 activity resulted in downregulation of Gfi1,
we did not observe reduced Gfi1 crosslinking to an autoregula-
tory site in the Gfi1 promoter (data not shown, Yucel et al.,
2004). Thus, loss of Gfi1 binding at the URE is likely a conse-
quence of displacement by PU.1. Collectively, these data
demonstrate that Gfi1 targets multiple regulatory regions within
the PU.1 locus and suggest that it restrains PU.1 expression
by interrupting an autoregulatory loop.
Apposed Gfi1 Motifs in PU.1 Target Sequences
To explore whether the molecular antagonism of PU.1 action
by Gfi1 via apposed binding sites may occur at other loci,
Figure 4. Attenuation of PU.1 Activity Promotes B Cell Fate Specifi-
cation
(A) shRNA-mediated targeting of transcripts encoding PU.1 in MPPs. WT
MPPs were transduced with a MSCV-shLuciferase or MSCV-shPU.1 vector.
GFP+ transductants were analyzed for the expression of PU.1 and c-fms
transcripts. Data are representative of two independent experiments.
(B) WT MPPs transduced with MSCV-shLuciferase (gray shaded area) or
MSCV-shPU.1 (black line) were plated on OP9 stroma and analyzed for the
presence of c-Kit+ precursors (gated on Mac1+ cells) 7 days after sorting.
Data are representative of two independent experiments.
(C)Gfi1/MPPs were transduced with MSCV-shLuciferase or MSCV-shPU.1
and analyzed by flow cytometry for the generation of Mac1+ and CD19+
precursors after 10 days.
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to identify PU.1 target genes in OHT-induced PUER cells. Bio-
informatic analysis (see Experimental Procedures) revealed
that 3170 PU.1 target sequences contained presumptive Gfi1
binding sites. Of these, 19% contained a putative PU.1 site
within 10 bp of a Gfi1 site (Figure S6D). Interestingly, PU.1
and Gfi1 motifs were seen to overlap in nearly half of this
subset of ChIP sequences. As a control, we generated a set
of randomized DNA sequences in silico with the same base
composition and length as the PU.1 target set. Comparison
between PU.1-bound and randomized DNA sequences re-
vealed a statistically significant difference given that only 9%
(SD = 0.44) of randomized sequences contained presumptive
binding sites for the two transcription factors separated by
10 bp or less.
Strikingly, the most notable arrangement of presumptive PU.1
and Gfi1 binding sites consisted of ones in which the core motif
of PU.1 (GGAA) and Gfi1 (AATC) overlapped by a single nucleo-
tide (Figure 6D, see Pim1). The fact that the same configuration
was retained as a predominant feature in the randomized
sequences, albeit at a substantially lower frequency, led us to
consider the possibility that the large frequency of overlapping
sites might be explained by compatibilities within the extended
binding motifs of PU.1 and Gfi1. In fact, inspection of the Gfi1
binding site matrix revealed preferences for specific nucleotides
flanking the core base pairs of the Gfi1 site that potentially
encode PU.1 sites (Figure 6D). Detailed analysis of the Gfi1
binding matrix revealed a number of preferred PU.1 site config-
urations in relation to the Gfi1 core, as evidenced in both the
PU.1 ChIP-on-chip and randomized DNA analysis (Figure 6D).
These analyses suggest that a large number of PU.1 target
Figure 5. Egr Activity in MPPs Antagonizes
B Cell Development
(A) WT MPPs transduced with a control vector
(MIGR1) or one expressing a dominant-negative
version of Egr2 (MIGR1-DEgr) were plated on
OP9 stroma and analyzed for Mac1+ and CD19+
precursors after 7 days.
(B) GFP+ transductants plated in limiting dilution
were analyzed for the generation of CD19+
progeny by flow cytometry 7 days after sorting.
Data are representative of at least three indepen-
dent experiments.
(C) Total bone marrow cells from WT, Egr1/,
Gfi1/, and Egr1/Gfi1/ animals were
analyzed for B lineage (B220+CD19+) and myeloid
(Mac1+) cells by flow cytometry. Data are repre-
sentative of three mice for each genotype.
genes may be repressed via competitive
binding or proximal action of Gfi1.
Ikaros Regulates Gfi1 and
Constrains PU.1 Expression
Given that Ikaros is required for B cell
development and repression of myeloid
potential, we examined whether its loss,
like that of Gfi1, also results in the
enhanced expression of PU.1 in MPPs.
PU.1 and c-fms transcripts were increased in Ikzf1/ MPPs
(Figure 7A and Figure S7A). In addition, the loss of Ikaros resulted
in a substantial increase in the expression of both c-fms and
FcgRII and III (Figure 7B). The similarities in themyeloid signature
observed in Gfi1/ and Ikzf1/ MPPs suggested a potential
relationship between Ikaros andGfi1activity in restrainingmyelo-
poiesis. Therefore, we sought to determine whether Ikaros
activity was required for the expression of Gfi1 in MPPs. Utilizing
a Gfi1-GFP reporter allele (Yucel et al., 2004), we observed that
the loss of Ikaros was associated with the generation of a subset
of MPPs expressing lower amounts of GFP (Figure 7C). We note
that a larger subset of Ikzf1/MPPs expressed higher amounts
of GFP relative to their control counterparts. These cells also ex-
pressed higher amounts of c-fms (data not shown) and may
represent MPPs that are primed to the myeloid lineage (Ng
et al., 2009). Bioinformatic analysis revealed several putative
Ikaros binding sites in theGfi1 locus. Interestingly, two such sites
werepositioneddownstreamof theGfi1gene in a170bp region
that is duplicated (Figure S7B). EMSA and ChIP assays demon-
strated that Ikaros bound these sites in vitro and in vivo (Figures
S7C and S7D). These data suggest that Ikaros directly promotes
Gfi1 expression in a subset of MPPs.
DISCUSSION
Using Sfpi1/ hematopoietic progenitors, we have previously re-
ported that a graded concentration of PU.1 regulates B lympho-
cyte versus macrophage cell fate choice (DeKoter and Singh,
2000). Consistent with these findings, it has been reported that
antagonizing the expression of PU.1 in differentiating mouse
embryonic stem cells with siRNA enhances their B lineage
Immunity 31, 576–586, October 16, 2009 ª2009 Elsevier Inc. 581
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strating a role for PU.1 dosage in innate versus adaptive cell fate
‘‘choice’’ in vivo has proven to be elusive. Using a sensitized
genetic background, a null mutation in the Gfi1 locus, we show
that reducing PU.1 concentration via a gene-dosage strategy
results in enhanced B lymphopoiesis. Importantly, these results
establish a role for PU.1 concentration in the regulation of myeloid
versusB lymphocytecell fatechoice invivo in thecontextofaMPP.
Recent studies have revealed that reducedPU.1 expression by
removal of a distal PU.1 enhancer resulted in a decrease, rather
than an increase, in bone marrow-derived B lineage progeny
in vivo (Rosenbauer et al., 2006). In these animals, removal of
the distal enhancer reduced PU.1 transcripts to less than 20%
Figure 6. Gfi1 Targets the PU.1 Locus
(A) PU.1 and Gfi1 compete for overlapping sites within the PU.1 URE. Binding
reactions containing either PU.1 and/or Gfi1 in vitro translation extracts with
radiolabeled oligonucleotides were analyzed by EMSA. Unlabelled PU.1 (lB)
and Gfi1 binding site oligonucleotides were used as competitor DNAs. Arrows
indicate migration positions of PU.1 or Gfi1 protein-DNA complexes.
(B) ChIP analysis of PU.1 (blue bars) and Gfi1 (red bars) to the URE in unstimu-
lated and OHT-treated PUER cells. Fold enrichment was assessed by qPCR
after normalization to a-actin. Data are representative of three experiments.
(C) ChIP-on-chip analysis of PU.1 target promoters in OHT-treated PUER
cells. Putative Gfi1 binding sites were identified in PU.1 target promoters
(see Experimental Procedures). The histogram displays the distribution of
the various configurations of overlapping presumptive PU.1 and Gfi1 binding
sites in the PU.1 ChIP sequences (blue bars). A randomized set of DNA
sequences (see Experimental Procedures) was used for generating a control
distribution (red bars). The Gfi1 binding site matrix is displayed below the
frequency distributions. The configurations of the overlapping presumptive
PU.1 and Gfi1 binding sites are tabulated on the basis of the distance (bp)
from the center of the Gfi1 core AATC to the center of the PU.1 core GGAA.
PU.1 core sequences that reside either upstream or downstream of the Gfi1
core sequence are denoted by negative or positive coordinates, respectively.
Error bars represent the standard deviation from the mean.582 Immunity 31, 576–586, October 16, 2009 ª2009 Elsevier Inc.of WT MPPs. It may be that reducing PU.1 concentration to
amounts observed in PU.1-enhancer-deficient animals is subop-
timal for initiating the B cell program in MPPs. It is also possible
that impaired B lymphopoiesis in these gene-targeted mice is
a consequence of enhanced generation of neutrophil precursors
(Rosenbauer et al., 2004). Lowering the concentration of PU.1
in relation to C/EBPa has been shown to promote the generation
of neutrophils (Dahl et al., 2003). Furthermore, because PU.1
can negatively regulate the expression of Gfi1 via the Egrs (Laslo
et al., 2006), Gfi-1 expression is likely to be increased in MPPs of
PU.1-enhancer-deficient animals. In this context, increased Gfi1
expression would function in concert with C/EBPa to promote
neutrophil development. Nonetheless, our results demonstrate
that PU.1 and Gfi1 have opposing roles in promoting myeloid
versusBcell development and establish that these counteracting
regulators function in a recurring manner to regulate cell fate
choice in the innate as well as the adaptive immune systems.
How does Gfi1 restrain the expression of PU.1 in MPPs to
specify the B cell fate? Previously, Gfi1 has been shown to
interact with the PU.1 protein, and this protein-protein interac-
tion has been suggested to inhibit PU.1mediated transactivation
(Dahl et al., 2007). Although we cannot rule out the involvement
of this protein interaction in antagonism of Sfpi1 gene expression
by Gfi1, we show that Gfi1 directly competes for PU.1 binding
in vitro and in vivo to autoregulatory sites in the PU.1 locus.
We therefore propose that Gfi1 represses Sfpi1 gene activation
by binding to DNA sites in the locus and disrupting a PU.1-
dependent autoregulatory loop. Importantly, increased expres-
sion of PU.1 can induce Egr expression, and the latter represses
Gfi1. Finally, Gfi1 has been shown to bind to its own promoter
and function in a negative autoregulatory loop (Yucel et al.,
2004). Thus, the two autoregulatory feedback loops and the
cross-antagonism between PU.1 and Gfi1 may generate alter-
nate gene-expression states within this network that are driven
by either higher PU.1 and Egr activity or higher Gfi1 activity.
Gfi1/ MPPs are poised to differentiate along the myeloid
lineage at the expense of the B lineage as a consequence of
misexpression of PU.1 and other myeloid genes. In addition to
the PU.1 locus, Gfi1 targets many myeloid genes, including
Csf1r (Zarebski et al., 2008). Accordingly, the absence of Gfi1 in
MPPs may augment the expression of PU.1 target genes, such
asCsf1r, via derepression.Our analysis of PU.1 target sequences
has revealed an intriguing feature: a large number of PU.1 core
motifs are embedded within the extended binding matrix for
Gfi1. Therefore, robust activation of such PU.1 target genes
would be dependent on displacement of Gfi1 repressor
complexes with PU.1 activator complexes at these composite
elements, and vice versa. We note that the predicted composite
sites are found in a varied set of genes, including growth factors
and their receptors, lineage-determining transcription factors,
and histone-modifying enzymes. We envision that the antago-
nistic regulation of a large battery of genes by PU.1 and Gfi1
would have evolved more readily by selecting for favorable
composite binding sites for the two factors rather than indepen-
dent selective events that generate two separated sites. This
may represent a general strategy for rapidly evolving counteract-
ing regulatory modules by utilizing transcription factors whose
individual binding motifs are compatible with the generation of
overlapping composite elements.
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and Represses PU.1
(A) RT-PCR analysis of the indicated transcripts in
WT and Ikzf1/ MPPs.
(B) Flow cytometric analysis of c-fms and
FcgRII&III expression on WT (gray shaded area)
and Ikzf1/ (black line) MPPs. Data are represen-
tative of three independent experiments.
(C) Expression of the Gfi1-GFP targeted allele in
MPPs from Gfi1+/ (gray shaded area) or Ikzf1/
Gfi1+/ (black line) mice by flow cytometry.
Data are representative of two independent
experiments.
(D) A proposed gene regulatory network (circuit
diagram) that dictates myeloid versus B cell fate
choice in the context of a MPP. Arrows represent
gene activation and barred lines represent gene
repression. Hatched lines represent regulatory
connections whose molecular basis remains to
be elucidated. The shaded region encompasses
a core gene regulatory network that is used in
a recurring manner for orchestrating innate as
well as adaptive immune cell fates.On the basis of the aforementioned data, we propose a tran-
scriptional regulatory network (circuit diagram) that appears to
function in a recurring manner to govern cell fate choice in the
immune system. In MPPs, PU.1 is proposed to function in
a graded manner to regulate B lymphoid versus macrophage
cell fates. A higher concentration of PU.1 represents a primary
input to the macrophage developmental program and can
induce the Egrs (module a). These regulators activate both
myeloid gene expression and the Id genes that inhibit E2A
activity (module b) and consequently the priming of B-lymphoid
developmental potential in MPPs (Dias et al., 2008). A lower
concentration of PU.1 along with Ikaros and E2A function as
primary inputs to activate the B lymphoid program. These factors
induce the B cell fate determinant EBF1 (module c) (Laslo et al.,
2008). In our model, the reduced concentration of PU.1 that
promotes B lymphoid development is achieved by Ikaros, in
part, through the induction of Gfi1. Ikaros and Gfi1 constrain
the expression of PU.1 while promoting the expression of B
lymphoid genes. We note that Ikaros has been implicated in
repression of the myeloid determinant C/EBPa (Reynaud et al.,
2008; Ng et al., 2009). This repressive activity of Ikaros is likely
to be important for B cell development, given that C/EBPa can
reprogram committed B cells into macrophages (Laiosa et al.,
2006a).
An additional consequence of Ikaros and Gfi1-mediated
repression of the myeloid program in MPPs could be to promote
T cell developmental potential. Along these lines, Gfi1 activity
appears to be critical for the generation of the earliest T lineage
progenitors in the thymus (Yucel et al., 2003). It is noteworthy
that the loss of Ikaros and Gfi1 is associated with the increased
expression of Id genes (Yucel et al., 2003; Ng et al., 2009). These
genes encode proteins that inhibit E2A family transcription
factors that are required for early B and T cell development
(Quong et al., 2002). Conversely, we have demonstrated thathigh concentrations of PU.1 induce Id2 during macrophage
differentiation (Laslo et al., 2006). Similarly, increasing PU.1
expression in fetal thymic progenitors induces Id2 and aspects
of the myeloid program (Franco et al., 2006). These findings
suggest a general mechanism by which Gfi1 and PU.1 could
function in a counteracting and recurring manner to promote B
and T lymphoid versus myeloid cell fates via the antagonistic
regulation of Id genes. Consistent with our model, Egr1 has
been identified as a positive regulator Id3 gene expression
(Bain et al., 2001; Quong et al., 2002). Loss of Egr1 results in an
increase in the absolute numbers of the earliest T lineage progen-
itors (Bettini et al., 2002). We note that multiple defects observed
in Gfi1/ mice during T cell development, including reduced
cellularity and impaired progression through the double-negative
and double-positive stages of development, are partially rescued
upon the loss of Egr1 in vivo (C.J.S. and H.S., unpublished data).
These findings are also in keepingwith our proposal that the Egrs
andGfi1comprise a counteracting regulatorymodule that directs
cell fate options or developmental transitions in multiple cellular
contexts (Laslo et al., 2006). On the basis of the above results,
the Ids would represent an additional node within this module
whose expression would be counteracted by Gfi1 to promote
lymphopoiesis or induced by PU.1 and the Egrs to inhibit B and
T cell potential.
Our proposed core transcriptional network for lymphoid
versus myeloid cell fate determination is derived from one that
regulates macrophage versus neutrophil cell fate choice (Laslo
et al., 2006). In the former, Ikaros has replaced C/EBPa as
a pivotal primary determinant, but the remaining circuit is
conserved both with respect to the nature of the regulatory
molecules and to their connectivity. The modified network archi-
tecture has two important evolutionary implications for the emer-
gence of the adaptive immune system from an innate primordial
precursor. First, it suggests that the conserved core networkImmunity 31, 576–586, October 16, 2009 ª2009 Elsevier Inc. 583
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predates the origin of lymphocytes and was co-opted by Ikaros.
Second, it suggests that Ikaros has played a key role in the evolu-
tionary emergence of adaptive immune cells (i.e., lymphocytes).
Ikaros manifests two major regulatory functions that are consis-
tent with this proposition: (1) It is able to restrain myeloid devel-
opmental potential by antagonizing expression of PU.1 and other
myeloid genes, and (2) it directly activates Rag gene expression
and promotes the recombination of antigen receptor gene
segments, a hallmark of adaptive immune cells (Reynaud et al.,
2008). Molecular phylogenetic analysis of our network compo-




Sfpi1+/ (Scott et al., 1994), Egr1+/ (Swiatek and Gridley, 1993), Egr2+/fl (Tail-
lebourg et al., 2002), Ikzf1+/ (Wang et al., 1996), andGfi1+/ (Yucel et al., 2004)
mice have been previously described. TheGfi1mutant allele represents a GFP
knockin, and the mutant mice are phenotypically indistinguishable from
previously describedGfi1 knockout animals (Karsunky et al., 2002). Therefore,
Gfi1GFP/GFPmice are referred to asGfi1/ in these studies.Wild-type C57BL/6
mice were purchased from the Jackson Laboratory. Mice were maintained in
pathogen-free conditions in accordance with guidelines approved by the Insti-
tutional Animal Care and Use Committees of the University of Chicago.
Flow Cytometry and Cell Culture
Bone marrow single-cell suspensions washed in PBS containing 5 mM EDTA
and 0.5% BSA were analyzed by flow cytometry with an LSRII (Becton
Dickinson) and FlowJo software. The following antibodies conjugated to
fluorescein isothiocyanate (FITC), phycoerythrin (PE), PerCPCy5.5, phycoery-
thrin-Cy7 (PE-Cy7), and allophycocyanin (APC) were used against cell-surface
molecules outlined in Table S5. DAPI was used for discriminating between
viable and dead cells. MPPs were isolated and cultured as previously
described (Medina et al., 2004) and analyzed for the presence of Mac1+ and
CD19+ cells between days 7–12 by flow cytometry.
Retroviral Transduction
WT MPPs were isolated as described above and transduced by coculture
with GFP (MIGR1), Gfi1 (MIGR1-Gfi1), or DEgr2 (MIGR1-DEgr) as previously
described (DeKoter and Singh, 2000). After 2 days, GFP+ transductants
were sorted and cultured on OP9 stroma in previously described B lineage
conditions (Medina et al., 2004) and analyzed for the presence of Mac1+ and
CD19+ cells by flow cytometry 7 days after sorting.
Plat-E packaging cells were transiently transfected with shRNA retroviral
constructs targeting luciferase (MSCV-shLuciferase) or PU.1 (MSCV-shPU.1)
with Fugene 6 reagent (Roche). WT or Gfi1/ MPPs were isolated as
described above and transduced as previously described (Reynaud et al.,
2008) and analyzed for the presence of Mac1+ and CD19+ cells by flow cytom-
etry 10 days after sorting. shRNA targeting sequences are available upon
request.
Gene-Expression Analysis
RNAwas isolated with TRIzol reagent (Invitrogen) and reverse-transcribedwith
a first-strand cDNA synthesis kit (GEHealthcare) in accordancewith themanu-
facturer’s instructions. Reverse-transcription products were serially diluted
and amplified by PCR for semiquantitative analyses. Brilliant SYBR Green
was used for quantitative PCR analyses on a Mx4000 system (Stratagene).
Expression was normalized relative to the expression of Hprt. Primer
sequences used for semiquantitative and quantitative PCR analyses are listed
in Tables S1 and S2.
Colony-Forming Assays
Clonogenic assays were performed by sorting300MPPs fromWT orGfi1/
mice in 3 ml of Methocult M3434 (Stem Cell Technologies) supplemented with
584 Immunity 31, 576–586, October 16, 2009 ª2009 Elsevier Inc.25 ng/ml of Flt3 ligand (R&DSystems). Approximately 100MPPswere plated in
duplicate in 35 mm petri dishes. After 8 days in culture, individual colonies
were counted, subjected to cytospin, and analyzed for the presence of
erythroid and/or myeloid colonies by Wright staining.
EMSA
PU.1 and Gfi1 proteins were generated with the TNT coupled reticulocyte
lysate system (Promega). IVT extracts were incubated for 30 min at RT with
a-32P-labeled double-stranded oligonucleotides representing an optimal
Gfi1 (Gfi1 consensus), a high affinity PU.1 (lB) binding site, or sites in the
PU.1 promoter and URE in a final volume of 20 ml of binding reaction buffer
(10 mM Tris [pH 7.5], 50 mM NaCl, 3% Ficoll, 1 mM EDTA, 1 mM DTT, and
1 mg/ml of polydI:dC). Ikaros binding reactions were performed as previously
described (Reynaud et al., 2008). EMSA probes are listed in Table S4.
ChIP
ChIP assays were performed in PUER cells treated with tamoxifen for 24 or
96 hr as previously described (Laslo et al., 2006) or EBF/ cells (Pongubala
et al., 2008) with some modifications. In brief, 1 3 107 cells were crosslinked
with 1% paraformaldehyde, sonicated, precleared, and incubated with 2 mg
of a-IgG (sc-2027; Santa Cruz), a-PU.1 (sc-352; Santa Cruz), a-Gfi1 (sc-
8558; Santa Cruz), preimmune, or a-Ikaros antiserum (Smale lab). Complexes
were washed with low and high salt buffers, eluted, and reverse-crosslinked,
and the DNA was precipitated. Immunoprecipitated DNA sequences were
analyzed by qPCR (primer sequences used for ChIP analyses are listed in
Table S3). For ChIP-on-chip, chromatin DNA samples were amplified by
ligation-mediated PCR and hybridized on a MM8 RefSeq promoter chip
(NimbleGen Systems).
Computational Analysis of PU.1 and Gfi1 Binding Sites
Genomic coordinates for all fragments bound by PU.1 with high confidence as
determined by NimbleScan (FDR score < 0.2) were extended by 500 bp
upstream and downstream, and these sequences were retrieved. MotifLoca-
tor was used for analyzing all ChIP sequences to predict PU.1 (M01172) and
Gfi1 (M00250) binding sites of quality t R 0.85. Algorithms were developed
in Perl so that the arrangement and distribution of PU.1 and Gfi1 binding sites
could be determined. Randomized sets of sequences were generated by
matching the length and base composition of the DNA sequences obtained
from the ChIP-on-chip data. Statistical analyses were based on 100 indepen-
dent randomized runs.
SUPPLEMENTAL DATA
Supplemental Data include seven figures and five tables and can be
found with this article online at http://www.cell.com/immunity/supplemental/
S1074-7613(09)00415-4.
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